CORD-19:038354e8830fe01feb621a12e8a8c467a15b6354 / 151542-151787 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/038354e8830fe01feb621a12e8a8c467a15b6354","sourcedb":"CORD-19","sourceid":"038354e8830fe01feb621a12e8a8c467a15b6354","text":"Ruprintrivir (AG7088) is currently being investigated as a highly potent (mean EC90 for 48 tested serotypes = 82 nM), peptidomimetic, irreversible 3C protease inhibitor (Dragovich et al., 1998a (Dragovich et al., ,b, 1999a Patick et al., 1999) .","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T946","span":{"begin":0,"end":245},"obj":"Sentence"},{"id":"T36131","span":{"begin":0,"end":245},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T946","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T36131","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T14","span":{"begin":0,"end":245},"obj":"Sentence"}],"attributes":[{"subj":"T14","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ec93d2","default":true},{"id":"CORD-19_Custom_license_subset","color":"#93ecec"}]}]}}